tradingkey.logo

ENHERTU Plus Pertuzumab Demonstrated Highly Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival Versus. THP As 1st-Line Therapy For Patients With HER2+ Metastatic Breast Cancer

ReutersApr 21, 2025 11:51 AM

- AstraZeneca PLC AZN.L:

  • ENHERTU® (FAM-TRASTUZUMAB DERUXTECAN-NXKI) PLUS PERTUZUMAB DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION-FREE SURVIVAL VERSUS. THP AS 1ST-LINE THERAPY FOR PATIENTS WITH HER2+ METASTATIC BREAST CANCER

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI